Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.